Novo preps big obesity push, undeterred by its rivals' fates by Carly Helfand Tuesday, November 21, 2017 Novo Nordisk is about to take on a task that’s so far foiled its peers: expanding the global obesity market.
Novo Nordisk cutting 185 jobs, adding another 70 in revamp by Eric Sagonowsky Friday, November 10, 2017 Still dealing with intense pricing pressure in its key diabetes business, Novo Nordisk is embarking on its latest wave of job cuts.
Novo Nordisk looks to GLP-1 meds to amp sales growth by Eric Sagonowsky Wednesday, November 1, 2017 Novo Nordisk is counting on multiple new drug launches—including the blockbuster-to-be semaglutide to help overcome market headwinds.
Novo petitions FDA to require Victoza copies to go through clinical trials by Eric Palmer Monday, October 9, 2017 Novo has filed a citizen petition saying Victoza’s manufacturing is so complex that equivalence of generics can't be certain without clinical trials.
Novo preps Saxenda sales drive in Latin America by Eric Sagonowsky Monday, May 22, 2017 Novo Nordisk is revving up for a push into Latin America with obesity drug Saxenda, hoping to put sales into a higher gear.
